AngioDynamics (ANGO) to Release Earnings on Wednesday

AngioDynamics (NASDAQ:ANGO - Get Free Report) is anticipated to announce its earnings results before the market opens on Wednesday, April 2nd. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $70.30 million for the quarter. AngioDynamics has set its FY 2025 guidance at -0.380--0.340 EPS and its FY25 guidance at ($0.38)-($0.34) EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million for the quarter, compared to the consensus estimate of $70.93 million. During the same period in the prior year, the firm earned ($0.05) EPS. The company's revenue for the quarter was down .1% compared to the same quarter last year. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Trading Down 3.4 %

Shares of AngioDynamics stock traded down $0.33 on Friday, hitting $9.50. 539,146 shares of the company traded hands, compared to its average volume of 571,638. The company has a market cap of $384.43 million, a PE ratio of -1.69 and a beta of 0.56. The stock's 50 day moving average price is $10.41 and its 200-day moving average price is $8.80. AngioDynamics has a 52 week low of $5.47 and a 52 week high of $13.50.

Remove Ads

Analyst Ratings Changes

Separately, HC Wainwright increased their price target on AngioDynamics from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, January 10th.

Insider Activity at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the firm's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares of the company's stock, valued at $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.40% of the stock is currently owned by corporate insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.